The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: A retrospective multicenter study (KMM160)

Korean Multiple Myeloma Working Party

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm, with rapidly progressing clinical course. We evaluated the treatment status and survival outcomes of 69 Korean patients with pPCL. Of them, 59 patients were treated; 15 (25.4%) were treated initially with novel agent-based regimens with upfront autologous stem cell transplantation (ASCT), 7 (11.9%) with conventional chemotherapy with upfront ASCT, 21 (35.6%) with novel agent-based regimens only, and 16 (27.1%) were treated with conventional chemotherapy alone. Overall response rates after initial therapy were significantly higher in patients treated with novel agentbased regimens compared with those treated with conventional chemotherapies (75% vs. 43.4%, P = 0.026). Median progression-free survival (PFS) and overall survival (OS) were 12.2 months and 16.1 months, respectively. The median PFS of the four treatment groups-conventional chemotherapy alone, novel agents alone, conventional chemotherapy with ASCT, and novel agents with ASCT-were 1.2, 9.0, 10.5, and 26.4 months, respectively (P < 0.001); the median OS of the four treatment groups were 2.9, 12.3, 14.1, and 31.1 months, respectively (P < 0.001). The median OS was also significantly better in the patients with novel agents with ASCT versus other patients. In a multivariate analysis, an increased lactate dehydrogenase level, low albumin (< 3.5 g/dL), and non-CR after front-line treatment were independently associated with poor PFS and OS. In conclusion, the use of novel agent-based therapy with ASCT and achieving a deep response to front-line treatment are important in expecting improved PFS and OS in patients with pPCL.

Original languageEnglish
Pages (from-to)79517-79526
Number of pages10
JournalOncotarget
Volume8
Issue number45
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Plasma Cell Leukemia
Stem Cell Transplantation
Multicenter Studies
Retrospective Studies
Disease-Free Survival
Survival
Drug Therapy
Therapeutics
Plasma Cell Neoplasms
L-Lactate Dehydrogenase
Albumins
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{121bebf6104243b9b4187377680c3b52,
title = "The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: A retrospective multicenter study (KMM160)",
abstract = "Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm, with rapidly progressing clinical course. We evaluated the treatment status and survival outcomes of 69 Korean patients with pPCL. Of them, 59 patients were treated; 15 (25.4{\%}) were treated initially with novel agent-based regimens with upfront autologous stem cell transplantation (ASCT), 7 (11.9{\%}) with conventional chemotherapy with upfront ASCT, 21 (35.6{\%}) with novel agent-based regimens only, and 16 (27.1{\%}) were treated with conventional chemotherapy alone. Overall response rates after initial therapy were significantly higher in patients treated with novel agentbased regimens compared with those treated with conventional chemotherapies (75{\%} vs. 43.4{\%}, P = 0.026). Median progression-free survival (PFS) and overall survival (OS) were 12.2 months and 16.1 months, respectively. The median PFS of the four treatment groups-conventional chemotherapy alone, novel agents alone, conventional chemotherapy with ASCT, and novel agents with ASCT-were 1.2, 9.0, 10.5, and 26.4 months, respectively (P < 0.001); the median OS of the four treatment groups were 2.9, 12.3, 14.1, and 31.1 months, respectively (P < 0.001). The median OS was also significantly better in the patients with novel agents with ASCT versus other patients. In a multivariate analysis, an increased lactate dehydrogenase level, low albumin (< 3.5 g/dL), and non-CR after front-line treatment were independently associated with poor PFS and OS. In conclusion, the use of novel agent-based therapy with ASCT and achieving a deep response to front-line treatment are important in expecting improved PFS and OS in patients with pPCL.",
author = "{Korean Multiple Myeloma Working Party} and Jung, {Sung Hoon} and Lee, {Je Jung} and Kihyun Kim and Cheolwon Suh and Yoon, {Dok Hyun} and Min, {Chang Ki} and Sohn, {Sang Kyun} and Choi, {Chul Won} and Lee, {Ho Sup} and Kim, {Hyo Jung} and Shin, {Ho Jin} and Bang, {Soo Mee} and Yoon, {Sung Soo} and Park, {Seong Kyu} and Yhim, {Ho Young} and Kim, {Min Kyoung} and Jo, {Jae Cheol} and Mun, {Yeung Chul} and Lee, {Jae Hoon} and Jinseok Kim",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.18535",
language = "English",
volume = "8",
pages = "79517--79526",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

The role of frontline autologous stem cell transplantation for primary plasma cell leukemia : A retrospective multicenter study (KMM160). / Korean Multiple Myeloma Working Party.

In: Oncotarget, Vol. 8, No. 45, 01.01.2017, p. 79517-79526.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of frontline autologous stem cell transplantation for primary plasma cell leukemia

T2 - A retrospective multicenter study (KMM160)

AU - Korean Multiple Myeloma Working Party

AU - Jung, Sung Hoon

AU - Lee, Je Jung

AU - Kim, Kihyun

AU - Suh, Cheolwon

AU - Yoon, Dok Hyun

AU - Min, Chang Ki

AU - Sohn, Sang Kyun

AU - Choi, Chul Won

AU - Lee, Ho Sup

AU - Kim, Hyo Jung

AU - Shin, Ho Jin

AU - Bang, Soo Mee

AU - Yoon, Sung Soo

AU - Park, Seong Kyu

AU - Yhim, Ho Young

AU - Kim, Min Kyoung

AU - Jo, Jae Cheol

AU - Mun, Yeung Chul

AU - Lee, Jae Hoon

AU - Kim, Jinseok

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm, with rapidly progressing clinical course. We evaluated the treatment status and survival outcomes of 69 Korean patients with pPCL. Of them, 59 patients were treated; 15 (25.4%) were treated initially with novel agent-based regimens with upfront autologous stem cell transplantation (ASCT), 7 (11.9%) with conventional chemotherapy with upfront ASCT, 21 (35.6%) with novel agent-based regimens only, and 16 (27.1%) were treated with conventional chemotherapy alone. Overall response rates after initial therapy were significantly higher in patients treated with novel agentbased regimens compared with those treated with conventional chemotherapies (75% vs. 43.4%, P = 0.026). Median progression-free survival (PFS) and overall survival (OS) were 12.2 months and 16.1 months, respectively. The median PFS of the four treatment groups-conventional chemotherapy alone, novel agents alone, conventional chemotherapy with ASCT, and novel agents with ASCT-were 1.2, 9.0, 10.5, and 26.4 months, respectively (P < 0.001); the median OS of the four treatment groups were 2.9, 12.3, 14.1, and 31.1 months, respectively (P < 0.001). The median OS was also significantly better in the patients with novel agents with ASCT versus other patients. In a multivariate analysis, an increased lactate dehydrogenase level, low albumin (< 3.5 g/dL), and non-CR after front-line treatment were independently associated with poor PFS and OS. In conclusion, the use of novel agent-based therapy with ASCT and achieving a deep response to front-line treatment are important in expecting improved PFS and OS in patients with pPCL.

AB - Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell neoplasm, with rapidly progressing clinical course. We evaluated the treatment status and survival outcomes of 69 Korean patients with pPCL. Of them, 59 patients were treated; 15 (25.4%) were treated initially with novel agent-based regimens with upfront autologous stem cell transplantation (ASCT), 7 (11.9%) with conventional chemotherapy with upfront ASCT, 21 (35.6%) with novel agent-based regimens only, and 16 (27.1%) were treated with conventional chemotherapy alone. Overall response rates after initial therapy were significantly higher in patients treated with novel agentbased regimens compared with those treated with conventional chemotherapies (75% vs. 43.4%, P = 0.026). Median progression-free survival (PFS) and overall survival (OS) were 12.2 months and 16.1 months, respectively. The median PFS of the four treatment groups-conventional chemotherapy alone, novel agents alone, conventional chemotherapy with ASCT, and novel agents with ASCT-were 1.2, 9.0, 10.5, and 26.4 months, respectively (P < 0.001); the median OS of the four treatment groups were 2.9, 12.3, 14.1, and 31.1 months, respectively (P < 0.001). The median OS was also significantly better in the patients with novel agents with ASCT versus other patients. In a multivariate analysis, an increased lactate dehydrogenase level, low albumin (< 3.5 g/dL), and non-CR after front-line treatment were independently associated with poor PFS and OS. In conclusion, the use of novel agent-based therapy with ASCT and achieving a deep response to front-line treatment are important in expecting improved PFS and OS in patients with pPCL.

UR - http://www.scopus.com/inward/record.url?scp=85030480154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030480154&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18535

DO - 10.18632/oncotarget.18535

M3 - Article

AN - SCOPUS:85030480154

VL - 8

SP - 79517

EP - 79526

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -